ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2115

Inflammatory Arthritis Treatment Outcomes at a First Nations Reserve Rheumatology Specialty Clinic

Erin Bell1, Sharon Leclercq2, Dianne P. Mosher1, Hani El-Gabalawy3, Tyler White4, Marvin Fritzler5 and Cheryl Barnabe2, 1University of Calgary, Calgary, AB, Canada, 2Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 3Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, 4Siksika Health Services, Siksika, AB, Canada, 5Medicine, University of Calgary, Calgary, AB, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Native Americans and inflammatory arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Health Services Research

Session Type: Abstract Submissions (ACR)

Background/Purpose: Inflammatory arthritis (IA: rheumatoid arthritis, systemic lupus erythematosus, and spondyloarthritis) disproportionately affects Canada’s First Nations population. Treatment outcomes may be ameliorated by health service models that mitigate logistical barriers to care and provide specialty services embedded in the primary care context. This study assessed the effectiveness of a specialized care model, delivered in a First Nations primary care setting, in achieving IA activity targets.

Methods: Consenting participants were recruited to an arthritis screening program held in a First Nations community between June 2011 and August 2012. Those determined to have IA (n=47) received ongoing follow-up with collection of disease activity measures and patient-reported outcomes, as well as treatment recommendations, at each visit. Repeated measures ANOVA was used to describe changes in disease activity measures over a 24 month period. The frequency with which a treatment change was recommended, based on moderate or high disease activity state determined from the DAS28, was calculated.

Results: A total of 131 visits by 47 participants (79% female, mean age 47 years, diagnosis of rheumatoid arthritis n=34) occurred over the 24 month study period. At the baseline visit, 70.6% of participants had moderate or high disease activity (DAS28>3.2). Significant decreases in joint counts (/28) were achieved (mean swollen joint count decrease of 7.0, 95% CI 3.5-10.4, p=0.0061; mean tender joint decrease of 7.2, 95% CI 4.1-10.3, p=0.0116). Patient-reported outcomes for pain, global assessment and physical function were not significantly improved during treatment. A recommendation for treatment change was made at 67% of visits where patients were classified in moderate or high disease activity. 

Conclusion: Although the program adequately addressed physician-derived disease activity targets, patient-reported outcomes were not significantly improved during follow-up. This suggests that the program should be modified to include a multi-disciplinary team that can address holistic aspects of First Nations health and reduce loss to follow-up from specialty care. A quality improvement initiative will be introduced to document reasons for deviation from the treat-to-target protocol.


Disclosure:

E. Bell,
None;

S. Leclercq,
None;

D. P. Mosher,
None;

H. El-Gabalawy,
None;

T. White,
None;

M. Fritzler,
None;

C. Barnabe,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammatory-arthritis-treatment-outcomes-at-a-first-nations-reserve-rheumatology-specialty-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology